Summit Master_rgb_png.png
Summit Announces BARDA Expands Ridinilazole Award by $8.8 Million to Include Additional NDA-Enabling Work
January 23, 2020 07:00 ET | Summit Therapeutics plc
Summit Therapeutics plc  (‘Summit’ or the ‘Company’) Summit Announces BARDA Expands Ridinilazole Award by $8.8 Million to Include Additional NDA-Enabling Work Total Committed BARDA...
DEINOVE selected for a presentation at BARDA Industry Day 2019 in Washington DC
October 15, 2019 12:30 ET | Deinove
DEINOVE selected for a presentation at BARDA Industry Day 2019 in Washington DC DEINOVE will present DNV3837/DNV3681, its antibiotic candidate targeting both urgent threats to public health and...
DEINOVE retenue pour une présentation au BARDA Industry Day 2019 à Washington DC
October 15, 2019 12:30 ET | Deinove
DEINOVE retenue pour une présentation au BARDA Industry Day 2019 à Washington DC DEINOVE présentera DNV3837/DNV3681, son candidat-antibiotique qui cible des pathogènes majeurs, tant en matière de...
Summit Awarded Additional $12 Million by BARDA for Phase 3 Development Programme of Ridinilazole for the Treatment of C. difficile Infection
August 16, 2018 07:00 ET | Summit Therapeutics plc
Brings Total Committed Funding Under BARDA Contract to $44 Million OXFORD, United Kingdom and CAMBRIDGE, Mass., Aug. 16, 2018 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT, AIM:SUMM), a...
Rapid Micro Biosystems logo
Rapid Micro Biosystems Awarded a Contract by Biomedical Advanced Research and Development Authority (BARDA) for the Implementation of a Rapid Sterility Test for Vaccines
October 23, 2017 07:00 ET | Rapid Micro Biosystems
LOWELL, Mass., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, a leading provider of automated, non-destructive, rapid microbial detection, is pleased to announce the receipt of a $7.3...
Summit Master_rgb_png.png
Summit Awarded BARDA Contract Worth Up to $62 Million to Support the Development of Ridinilazole for the Treatment of C. difficile Infection
September 11, 2017 07:00 ET | Summit Therapeutics PLC
CAMBRIDGE, Mass. and OXFORD, United Kingdom, Sept. 11, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for...
LOGO JPG.jpg
Cempra Authorized to Receive Funds From BARDA for a Phase 2/3 Clinical Trial of Solithromycin in Pediatric Patients
March 07, 2016 07:00 ET | Melinta Therapeutics, Inc.
Phase 2/3 Pivotal Trial Will Test Intravenous, Oral Capsule and Oral Suspension Formulations of Solithromycin in Pediatric Patients From Age 2 Months to 17 Years Cempra to Receive $25.5...
LOGO JPG.jpg
Cempra to Receive BARDA Funding for 1b and Start-Up of Phase 2/3 Solithromycin Pediatric Studies
November 19, 2014 06:00 ET | Melinta Therapeutics, Inc.
$16.0 Million Will be Provided to Cover the Cost of the Study and Other Activities Specified in the Contract Phase 1b and Phase 2/3 Studies Will Test Intravenous, Oral Capsule and Oral Suspension...
VaxInnate Logo
VaxInnate Quadrivalent Seasonal Influenza Vaccine Candidate, VAX2012Q, Meets Phase 1 Seasonal Influenza Endpoints
November 11, 2014 08:00 ET | VaxInnate Corporation
Cranbury, NJ, Nov. 11, 2014 (GLOBE NEWSWIRE) -- VaxInnate Corporation, a biotechnology firm pioneering next-generation vaccine technology, announced today that enrollment has concluded in the Phase 1...
VaxInnate Logo
VaxInnate Updates Plans to Advance Lead Vaccine Candidate, VAX2012Q in Elderly
October 08, 2014 09:00 ET | VaxInnate Corporation
Cranbury, NJ, Oct. 8, 2014 (GLOBE NEWSWIRE) -- VaxInnate Corporation, a biotechnology firm pioneering a breakthrough vaccine technology platform, provided an update on clinical development plans for...